meta_pixel
Tapesearch Logo
Log in
Honestly with Bari Weiss

Will Ozempic Solve Obesity in America? A Debate

Honestly with Bari Weiss

The Free Press

News, Society & Culture

4.67.8K Ratings

🗓️ 15 February 2023

⏱️ 76 minutes

🧾️ Download transcript

Summary

Ozempic, the brand name drug for a medication called semaglutide, is one of the most popular drugs on the market right now. Originally developed to treat type 2 diabetes, the injectable drug has recently boomed in popularity for its off-label use to help people lose weight... fast. Celebrities and public figures have admitted they're taking it. Instagram influencers are showing off remarkable before and after photos. It's been called "TikTok's favorite weight loss drug." As one doctor said, "we haven't seen a prescription drug with this much cocktail and dinner chatter since Viagra came to the market." But alongside the rise in Ozempic prescriptions come many questions still unknown: Who should be taking it? Is it safe for longterm use? Who is it safe for? Should children be prescribed it to treat childhood obesity, as the American Academy of Pediatrics recently advised? Is Ozempic a permanent solution to the obesity epidemic? Or is it more like a bandaid, a quick fix that does little to address the root causes of obesity? And, to that end, what is the root cause of obesity? Is it a "brain disease," as one Harvard doctor recently declared on 60 Minutes that warrants medication? Or do diet, exercise, willpower and other behavioral lifestyle choices still matter? These are questions that my guests do not agree on. Dr. Chika Anekwe is an obesity medicine physician at Massachusetts General Hospital and an instructor in medicine at Harvard Medical School. Dr. Vinay Prasad is a hematologist-oncologist and a professor at the University of California San Francisco. His most recent book is Malignant: How Bad Policy and Bad Evidence Harm People with Cancer. And Calley Means is a former consultant for food and Pharma companies who now works to expose their practices and instead incentive healthy food as the foundation of health policy. Today, Dr. Anekwe, Dr. Prasad, and Means debate: will Ozempic solve obesity in America? Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0

Bam, picture this! You're watching your favorite artist play. Not that artist!

0:05.0

Ha ha, yeah, that's you! You look down at the red can in your hand, or is it?

0:11.0

No, it's a Pepsi Max.

0:13.0

The COLA over 70% of the UK prefer.

0:16.0

You props prefer it too. Go on, try it.

0:19.0

Pepsi Max. Lastly for more.

0:23.0

UK Blind Taste Test with over 54,000 people versus UK's biggest selling full sugarcola.

0:27.6

For verification go to Pepsi.

0:28.9

Code at UK slash FAQ.

0:32.2

I'm Barry Weiss. This is honestly and today we're diving deep into the biggest

0:37.4

and maybe the most contentious drug on the market right now. Ozempik.

0:44.0

Ozempik.

0:46.0

Ozempik is proven to lower A1C.

0:49.0

Most people who took Ozempik reached an A1C under 7 and maintained it.

0:53.7

And you may lose weight.

0:55.0

Adults lost on average up to 12 pounds.

0:58.9

OZEMPIC is the brand name for a medication

1:00.8

called Someglutide.

1:02.4

And while it was developed and has been used for years

1:04.6

to treat type 2 diabetes.

1:06.1

We're going to get back in your type 2 diabetes zone,

1:08.4

ask your health care provider today

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from The Free Press, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Free Press and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.